Skip to main content
CYAN
OTC Life Sciences

Cyanotech Finalizes "Going Private" Transaction, Sets $0.47 Cash-Out Price and February 9 Effective Date

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
9
Price
$0.5
Mkt Cap
$3.696M
52W Low
$0.21
52W High
$0.6
Market data snapshot near publication time

summarizeSummary

Cyanotech Corporation has filed an amendment to finalize the terms of its "going private" transaction, setting a cash-out price of $0.47 per share for small stockholders and an effective date of February 9, 2026, leading to deregistration and delisting.


check_boxKey Events

  • Transaction Finalized

    The company has finalized the terms for its "going private" transaction, following the initial SC 13E3 filing on January 12, 2026.

  • Cash-Out Price Set

    Stockholders owning fewer than 400 pre-Reverse Split shares will receive $0.47 per share in cash.

  • Effective Date Confirmed

    The Reverse/Forward Stock Split is expected to be effective on or around February 9, 2026.

  • Deregistration and Delisting

    The company plans to deregister its common stock and suspend SEC reporting, leading to its removal from the OTCQB.


auto_awesomeAnalysis

This amendment provides the definitive terms and timeline for Cyanotech's "going private" transaction, which was previously announced. The company will execute a 400-for-1 reverse stock split followed by a 1-for-400 forward split, effectively cashing out stockholders holding fewer than 400 shares at $0.47 per share. This price is slightly below the current market price but above the 90-day average. The primary implication for investors is the cessation of public reporting and delisting from the OTCQB, which will significantly reduce transparency and liquidity. While the company cites substantial cost savings as the rationale, this move fundamentally alters the investment landscape for current public shareholders, removing their ability to trade shares on a public market and eliminating SEC oversight.

At the time of this filing, CYAN was trading at $0.50 on OTC in the Life Sciences sector, with a market capitalization of approximately $3.7M. The 52-week trading range was $0.21 to $0.60. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed CYAN - Latest Insights

CYAN
Feb 13, 2026, 2:09 PM EST
Filing Type: SC 13E3/A
Importance Score:
9
CYAN
Feb 03, 2026, 5:18 PM EST
Filing Type: SC 13E3/A
Importance Score:
9
CYAN
Jan 12, 2026, 12:12 PM EST
Filing Type: SC 13E3
Importance Score:
9